Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
Staar Surgical Co (STAA) delivers innovative vision correction solutions through advanced implantable lenses for refractive and cataract surgery. This news hub provides investors and medical professionals with essential updates on the company's technological advancements and market position.
Access consolidated coverage of earnings reports, product approvals, and strategic partnerships impacting the ophthalmic devices sector. Our repository includes official press releases about ICL technology developments, international regulatory milestones, and clinical study outcomes.
Stay informed about STAA's progress in minimally invasive surgical solutions through verified updates on manufacturing expansions, R&D investments, and surgeon training initiatives. Bookmark this page for real-time tracking of developments affecting the company's role in improving global vision care standards.
Broadwood Partners (owner of 30.2% of STAAR Surgical, NASDAQ: STAA) on Dec 9, 2025 responded to Alcon Inc.'s (NYSE: ALC) amended acquisition terms, urging shareholders to vote AGAINST the proposed sale. Broadwood says the board ran a flawed process, delayed votes three times, rejected other bidders, added a limited go‑shop, and accepted only a $150 million price bump (to $30.75 per share from $28). Broadwood highlights a $24 million CEO payout under original terms and asserts STAAR is worth substantially more as an independent company if management projections are met.
Alcon (SIX/NYSE: ALC) announced an amended merger agreement to acquire STAAR Surgical (NASDAQ: STAA) for $30.75 per share in cash, increasing the offer by roughly $150 million of equity value. The transaction represents an approximate $1.6 billion total equity value, a 74% premium to STAAR’s 90-day VWAP and a 66% premium to STAAR’s August 4, 2025 closing price.
Alcon said it will finance the deal with short- and long-term credit facilities, expects the merger to be accretive to earnings in year two, and anticipates closing in early 2026, subject to regulatory and STAAR stockholder approvals. STAAR stockholders are urged to vote ahead of a December 19, 2025 meeting.
STAAR Surgical (NASDAQ: STAA) and Alcon (NYSE: ALC) agreed amendments to their merger agreement that create a new 30-day go-shop allowing STAAR to solicit third-party proposals through December 6, 2025. Under the amendment, Alcon waives matching rights and limited information rights during the go-shop, and STAAR will not pay a termination fee if it accepts a superior qualified proposal.
The companies said Alcon will engage with STAAR stockholders and proxy advisors. STAAR postponed its Special Meeting to vote on the merger to December 19, 2025 (previously December 3, 2025); stockholders of record as of October 24, 2025 remain entitled to vote.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
